Acute Myeloid Leukemia (AML) Treatment Market size in APAC to grow by USD 277.03 Million | Driven by high incidence of acute myeloid leukemia | Technavio – PR Newswire

Searching for your content…
In-Language News
Contact Us
888-776-0942
from 8 AM – 10 PM ET
News provided by
Mar 07, 2022, 05:00 ET
Share this article
NEW YORK, March 7, 2022 /PRNewswire/ — "Acute Myeloid Leukemia (AML) Treatment Market in APAC by Type and Geography – Forecast and Analysis 2022-2026" has been added to Technavio’s offering. The market is expected to witness a YOY growth of 12.56% in 2022 and is anticipated to grow at a CAGR of 12.83% between 2021 and 2026. The report segments the market by type (chemotherapy, stem cell transplantation, and others) and geography (China, Japan, India, and Rest of APAC).
For more insights on YOY and CAGR, Read our FREE Sample Report
Vendor Insights 
The acute myeloid leukemia (AML) treatment market in APAC is fragmented due to the presence of many local and global players. These vendors are consistently investing in the latest technologies to develop advanced treatment options for AML. Vendors are partnering with research organizations and hospitals for R&D and are participating in various scientific conferences to showcase their products. They are also focusing on other aspects such as product approvals, M&A, and new product launches to gain a competitive edge in the market.
The report analyzes the market’s competitive landscape and offers information on several market vendors, including:
Find additional highlights on the growth strategies adopted by vendors and their product offerings, Read Free Sample Report. 
Regional Market Analysis 
China will provide maximum growth opportunities for market vendors during the forecast period. According to our research report, the country will contribute to 40% of the global market growth and is expected to dominate the market through 2026. The increasing demand for personalized drugs and the expected approvals between 2020 and 2023 of several therapies will be crucial in driving the growth of the acute myeloid leukemia (AML) treatment market in APAC. However, the market will witness faster growth in India during the forecast period.  
Know more about this market’s geographical distribution along with the detailed analysis of the top regions. https://www.technavio.com/report/acute-myeloid-leukemia-aml-treatment-market-industry-in-apac-analysis
Key Segment Analysis
By type, the market share by the chemotherapy segment will be significant during the forecast period. The growth of the segment can be attributed to the availability of many chemotherapy drugs for AML in APAC. Also, the presence of large pharmaceutical players such as Novartis AG, Pfizer Inc., Teva Pharmaceuticals, AbbVie Inc, with highly effective chemotherapy drugs for the treatment of AML will be crucial in driving the growth of the segment.
View FREE Sample: to know additional highlights and key points on various market segments and their impact in coming years.
Key Market Drivers & Challenges: 
The acute myeloid leukemia (AML) treatment market is primarily driven by the high incidence of AML. Countries in APAC have been experiencing a rise in the number of AML cases over the years. For instance, in 2021, the estimated number of new cases in Australia was 4,903. Similarly, every year in New Zealand, around 700 adults and 40 children are diagnosed with leukemia. The high incidence of the condition is increasing the demand for drugs to treat AML, which is driving the growth of the market.
However, the lack of adequate healthcare infrastructure in many developing countries in APAC will reduce the growth potential in the market. Many developing and underdeveloped economies in APAC lack proper healthcare infrastructure due to limited healthcare budgets. This has limited the number of healthcare institutions that use advanced radiotherapy systems for cancer treatment, which is expected to have a negative impact on the growth of the market.
Download a free sample for highlights on market Drivers & Challenges affecting the acute myeloid leukemia (AML) treatment market.
Customize Your Report 
Don’t miss out on the opportunity to speak to our analyst and know more insights about this market report. Our analysts can also help you customize this report according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.  
We offer USD 1,000 worth of FREE customization at the time of purchase. Speak to our Analyst now! 
Related Reports:
Chronic Myelogenous Leukemia Therapeutics Market by Product and Geography Global Forecast and Analysis 2022-2026
Monoclonal Antibodies Market by Application and Geography Forecast and Analysis 2022-2026
Acute Myeloid Leukemia (AML) Treatment Market in APAC: Scope
Report Coverage
Details
Page number
120
Base year
2021
Forecast period
2022-2026
Growth momentum & CAGR
Accelerate at a CAGR of 12.83%
Market growth 2022-2026
USD 277.03 million
Market structure
Fragmented
YoY growth (%)
12.56
Regional analysis
China, Japan, India, and Rest of APAC
Performing market contribution
China at 40%
Key consumer countries
China, Japan, India, and Rest of APAC
Competitive landscape
Leading companies, competitive strategies, consumer engagement scope
Companies profiled
AbbVie Inc., Agios Inc., Astellas Pharma Inc., Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Novartis AG, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.
Market Dynamics
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for the forecast period.
Customization purview
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.
Table of Contents:
1. Executive Summary                           
                1.1 Market Overview
                                Exhibit 01:  Key Finding 1
                                Exhibit 02:  Key Finding 2
                                Exhibit 03:  Key Finding 3
                                Exhibit 04:  Key Finding 5
                                Exhibit 05:  Key Finding 6
                                Exhibit 06:  Key Finding 7
2. Market Landscape                             
                2.1 Market ecosystem             
                                Exhibit 07:  Parent market
                                Exhibit 08:  Market Characteristics
                2.2 Value Chain Analysis          
                                Exhibit 09:  Value chain analysis:  Pharmaceuticals
                                2.2.1    Research and development (R&D) and drug discovery
                                2.2.2    Integration and product development
                                2.2.3    Manufacturing
                                2.2.4    Outbound logistics
                                2.2.5    Marketing and sales
                                2.2.6    Support activities
                                2.2.7    Innovation
3. Market Sizing                       
                3.1 Market definition
                                Exhibit 10:  Offerings of vendors included in the market definition
                3.2 Market segment analysis 
                                Exhibit 11:  Market segments
                3.3 Market size 2020 
                3.4 Market outlook: Forecast for 2020 – 2025 
                                3.4.1Estimating growth rates for emerging and high-growth markets
                                3.4.2    Estimating growth rates for mature markets
                                Exhibit 12:  Global – Market size and forecast 2021 – 2026 (million $)
                                Exhibit 13:  Global market: Year-over-year growth 2021 – 2026 (%)
4. Five Forces Analysis                          
                4.1 Five Forces Summary        
                                Exhibit 14:  Five forces analysis 2021 – 2026
                4.2 Bargaining power of buyers           
                                Exhibit 15: Bargaining power of the buyer
                4.3 Bargaining power of suppliers       
                                Exhibit 16: Bargaining power of the supplier
                4.4 Threat of new entrants    
                                Exhibit 17: Threat of new entrants
                4.5 Threat of substitutes         
                                Exhibit 18: Threat of substitutes
                4.6 Threat of rivalry   
                                Exhibit 19: Threat of rivalry
                4.7 Market condition
                                Exhibit 20: Market condition – Five forces 2021
5. Market Segmentation by Type
                5.1 Market segments
                                Exhibit 21: Type- Market share 2021-2026 (%)
                5.2 Comparison by Type          
                                Exhibit 22:  Comparison by Type
                5.3 Chemotherapy – Market size and forecast 2021-2026           
                                Exhibit 23:  Chemotherapy- Market size and forecast 2021-2026 ($ billion)
                                Exhibit 24:  Chemotherapy- Year-over-year growth 2021-2026 (%)
                5.4 Stem cell transplantation – Market size and forecast 2021-2026       
                                Exhibit 25:  Stem cell transplantation – Market size and forecast 2021-2026 ($ billion)
                                Exhibit 26:  Stem cell transplantation- Year-over-year growth 2021-2026 (%)
                5.5 Others – Market size and forecast 2021-2026           
                                Exhibit 27:  Others – Market size and forecast 2021-2026 ($ billion)
                                Exhibit 28:  Others- Year-over-year growth 2021-2026 (%)
                5.6 Market opportunity by Type          
                                Exhibit 29:  Market opportunity by Type
6. Customer landscape                         
                                Technavio’s customer landscape matrix comparing Drivers or price sensitivity, Adoption lifecycle, importance in customer price basket, Adoption rate and Key purchase criteria
                                Exhibit 30:  Customer landscape
7 Geographic Landscape
                7.1 Geographic segmentation
                                Exhibit 31:  Market share by geography 2021-2026 (%)
                7.2 Geographic comparison   
                                Exhibit 32:  Geographic comparison
                7.3 China – Market size and forecast 2021-2026             
                                Exhibit 33:  China – Market size and forecast 2021-2026 ($ million)
                                Exhibit 34:  China – Year-over-year growth 2021-2026 (%)
                7.4 Japan – Market size and forecast 2021-2026             
                                Exhibit 35:  Japan – Market size and forecast 2021-2026 ($ million)
                                Exhibit 36:  Japan – Year-over-year growth 2021-2026 (%)
                7.5 India – Market size and forecast 2021-2026               
                                Exhibit 37:  India – Market size and forecast 2021-2026 ($ million)
                                Exhibit 38:  India – Year-over-year growth 2021-2026 (%)
                7.6 Rest of APAC – Market size and forecast 2021-2026               
                                Exhibit 39:  Rest of APAC – Market size and forecast 2021-2026 ($ million)
                                Exhibit 40:  Rest of APAC – Year-over-year growth 2021-2026 (%)
                7.7 Key leading countries        
                                Exhibit 41:  Key leading countries
                7.8 Market opportunity by geography
                                Exhibit 42:  Market opportunity by geography ($ million)
8. Drivers, Challenges, and Trends                   
                8.1 Market drivers     
                                8.1.1    High incidence of acute myeloid leukemia
                                8.1.2    Advancements in pharmacology and molecular biology in APAC
                                8.1.3    Rising adoption of generic drugs
                8.2 Market challenges              
                                8.2.1    Lack of adequate healthcare infrastructure in developing nations
                                8.2.2    Complications related to chemotherapy
                                8.2.3    High cost of treatment
                                Exhibit 43:  Impact of drivers and challenges
                8.3 Market trends      
                                8.3.1    CAR T-cell therapy for AML
                                8.3.2    Approval of new treatment methods
                                8.3.3    Increase in awareness programs
9. Vendor Landscape                             
                9.1 Overview
                                Exhibit 44:  Vendor landscape
                9.2 Landscape disruption        
                                Exhibit 45: Landscape disruption
                                Exhibit 46: Industry Risk
10. Vendor Analysis               
                10.1 Vendors Covered             
                                Exhibit 47: Vendor Landscape
                10.2 Market positioning of vendors    
                                Exhibit 48: Market positioning of vendors
                10.3 AbbVie Inc.         
                                Exhibit 49:  AbbVie Inc. – Overview
                                Exhibit 50:  AbbVie Inc. – Business segments
                                Exhibit 51:  AbbVie Inc. – Key offerings
                                Exhibit 52:  AbbVie Inc. – Segment focus
                10.4 Agios Inc.
                                Exhibit 53:  Agios Inc.  – Overview
                                Exhibit 54:  Agios Inc.  – Business segments
                                Exhibit 55:  Agios Inc.  – Key offerings
                                Exhibit 56:  Agios Inc.  – Segment focus
                10.5 Astellas Pharma Inc.        
                                Exhibit 57:  Astellas Pharma Inc. – Overview
                                Exhibit 58:  Astellas Pharma Inc. – Product and service
                                Exhibit 59:  Astellas Pharma Inc. – Key offerings
                10.6 Bristol Myers Squibb Co.
                                Exhibit 60:  Bristol Myers Squibb Co. – Overview
                                Exhibit 61:  Bristol Myers Squibb Co. – Product and service
                                Exhibit 62:  Bristol Myers Squibb Co. – Key offerings
                10.7 Daiichi Sankyo Co. Ltd.   
                                Exhibit 63:  Daiichi Sankyo Co. Ltd. – Overview
                                Exhibit 64:  Daiichi Sankyo Co. Ltd. – Business segments
                                Exhibit 65:  Daiichi Sankyo Co. Ltd. – Key offerings
                                Exhibit 66:  Daiichi Sankyo Co. Ltd. – Segment focus
                10.8 F. Hoffmann La Roche Ltd.
                               Exhibit 67:  F. Hoffmann La Roche Ltd. – Overview         
                               Exhibit 68:  F. Hoffmann La Roche Ltd. – Business segments      
                              Exhibit 69:  F. Hoffmann La Roche Ltd. – Key offerings   
                              Exhibit 70:  F. Hoffmann La Roche Ltd. – Segment focus
                10.9 GlaxoSmithKline Plc         
                                Exhibit 71:  GlaxoSmithKline Plc – Overview
                                Exhibit 72:  GlaxoSmithKline Plc – Business segments
                                Exhibit 73:  GlaxoSmithKline Plc – Key offerings
                                Exhibit 74:  GlaxoSmithKline Plc – Segment focus
                10.10 Novartis AG      
                                Exhibit 75:  Novartis AG – Overview
                                Exhibit 76:  Novartis AG – Business segments
                                Exhibit 77:  Novartis AG – Key offerings
                                Exhibit 78:  Novartis AG – Segment focus
                10.11 Pfizer Inc.          
                                Exhibit 79:  Pfizer Inc. – Overview
                                Exhibit 90:  Pfizer Inc. – Product and service
                                Exhibit 91:  Pfizer Inc. – Key News
                                Exhibit 92:  Pfizer Inc. – Key offerings
                10.12 Teva Pharmaceutical Industries Ltd.       
                                Exhibit 93:  Teva Pharmaceutical Industries Ltd. – Overview
                                Exhibit 94:  Teva Pharmaceutical Industries Ltd. – Business segments
                                Exhibit 95:  Teva Pharmaceutical Industries Ltd. – Key offerings
                                Exhibit 96:  Teva Pharmaceutical Industries Ltd. – Segment focus
11. Appendix                            
                11.1 Scope of the report         
                                11.1.1 Market definition
                                11.1.2 Objectives
                                11.1.3 Notes and caveats
                11.2 Currency conversion rates for US$            
                                Exhibit 97: Currency conversion rates for US$
                11.3 Research Methodology 
                                Exhibit 98: Research Methodology
                                Exhibit 99: Validation techniques employed for market sizing
                                Exhibit 100: Information sources
                11.4 List of abbreviations        
                                Exhibit 101: List of abbreviations
About Us: 
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. 
Contact 
Technavio Research 
Jesse Maida 
Media & Marketing Executive 
US: +1 844 364 1100 
UK: +44 203 893 3200 
Email: [email protected] 
Website: www.technavio.com/
SOURCE Technavio
More news releases in similar topics
Cision Distribution 888-776-0942
from 8 AM – 9 PM ET

source

Share:

Pulse Handshak

Pulse Handshak

Collaborative online survey tool for the market research industry. Remote assisted surveying just like face-to-face interviews. Here interviewers can talk to the respondent over the web-console without the need for any other communication channel and share the same Q're with responses and click actions.

Pulse FE

Pulse FE

Pulse Field Expert or Pulse FE is the main platform for both offline and online survey at softofficepro.com. It is robust and used by hundreds of clients over tens of years with millions of responses. Do it once Q're and deploy on both offline devices (android) and online forms makes it a great cost effective platform for any kind of responses

Pulse Ultimate

Pulse Ultimate

Pulse Ultimate is targeted for tracking studies and retail audits. An offline survey system offering extreme field control including processes like data quality check, back-check, rework, comparison with previous wave data etc. helps to get the best results on a day-to-day basis

More Posts